Formulation, development and in vitro evaluation of taste masking mouth dissolving tablet of levocetirizine dihydrochloride
Abstract
Levocetirizine dihydrochloride is a selective, long acting peripheral H1receptor antagonist. Allergic rhinitis is a symptomatic disorder of the nose induced by inflammation mediated by immunoglobulin E (IgE) in the membrane lining the nose after allergen exposure. Thus formulating Levocetirizine into an mouth dissolving tablet dosage form would provide fast relief. The Levocetirizine is bitter in taste so the Kyron T-114 (ion exchange resin) was used to mask the taste and to formulate an mouth dissolving tablet dosage form using drug resin complex. The tablets were evaluated for the drug content, weight variation, water absorption ratio, wetting time, in vitro disintegration, dispersion time, hardness, friability, thickness uniformity. The tablets disintegrated in vitro within 22 to 66 seconds complete drug were released from tablet within 10 minutes.
Read the paper
Related studies
- Artificial Intelligence in Medicine: Cross-Sectional Study Among Medical Students on Application, Education, and Ethical Aspects
- Information quality of videos related to esophageal cancer on tiktok, kwai, and bilibili: a cross-sectional study
- The quality and reliability of short videos about hypertension on TikTok: a cross-sectional study
- Quality and reliability evaluation of pancreatic cancer-related video content on social short video platforms: a cross-sectional study
- Quality and reliability of pediatric pneumonia related short videos on mainstream platforms: cross-sectional study
- Association between metabolic score for insulin resistance (METS-IR) and hypertension: a cross-sectional study based on NHANES 2007–2018
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.